Mike Doustdar seeks to reassure investors that Novo Nordisk's Wegovy pill will drive profitable growth despite pricing pressures
Novo Nordisk CEO Mike Doustdar stated that the company's Wegovy pill is positioned to drive profitable growth despite ongoing pricing pressures. While the company reported better-than-expected adjusted sales and operating profit for the second quarter, investors remain focused on the competitive landscape and the company's ability to maintain momentum. Mike Doustdar noted that lower prices are driving strong demand and that the company is seeking a "sweet spot" between pricing and volume. The Wegovy pill has already reached over 5 million prescriptions, with 80% of patients using the pill for the first time. This indicates that the pill is expanding the obesity market rather than just drawing users away from the injectable version. However, the company faces intense competition from Eli Lilly, which has rapidly gained market share with its tirzepatide-based therapies. Analysts suggest that while the company's current performance is solid, the long-term success will depend on the execution of its next-generation drugs and its ability to navigate the U.S. market's pricing challenges.